BioStock: Arcede Pharma and Iconovo receive funding from Swelife

Arcede Pharma, Iconovo and Lund University has received just over 2 MSEK from Swelife for the development of the inhaled treatment RCD405 for COPD and severe asthma. The grant will be used to develop an inhalation product for use in clinical studies and continue to study the candidate’s dual mechanism of action.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/04/arcede-pharma-and-iconovo-receive-funding-from-swelife/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se